Wu Bin 武滨
Companies 任职公司
| Company 公司 | Industry 行业 | Role 职务 | Since 起始 | Grade 评级 |
|---|---|---|---|---|
| Dezhan Healthcare 德展健康 | Chemical Pharmaceuticals | Independent Director | 12 Sep 2025 | E |
| Realcan Pharmaceutical Group 瑞康医药 | Pharmaceutical Distribution | Independent Director | 19 Aug 2026 | D |
| Zhejiang Wecome Pharmaceutical 维康药业 | Traditional Chinese Medicine | Independent Director | 20 May 2024 | D |
| Shandong Keyuan Pharmaceutical 科源制药 | Chemical Pharmaceuticals | Non-independent Director | 30 Sep 2024 | C |
| Yabao Pharmaceutical 亚宝药业 | Traditional Chinese Medicine | Non-independent Director | 16 Jun 2026 | B |
| Lbx Pharmacy Chain 老百姓 | Pharmaceutical Distribution | Non-independent Director | 22 Feb 2024 | C |
Biography 简历
武滨先生,1960年6月出生,中国国籍,无境外永久居留权,硕士研究生学历,注册高级咨询师,高级经济师,执业药师。历任山西省医药公司企业管理科副科长,山西省医药管理局商业处副处长,山西省药材公司副经理,山西省医药集团有限公司经济运行部部长、总经理助理,中国医药商业协会常务副会长。2020年8月至今担任中国医药企业管理协会专家委员会委员。2016年5月至今任老百姓大药房连锁股份有限公司董事,2016年9月至2023年5月任瑞康医药集团股份有限公司独立董事,2017年3月至2023年1月任广誉远中药股份有限公司独立董事,2019年7月至今任哈药集团人民同泰医药股份有限公司独立董事,2021年8月至今任德展大健康股份有限公司独立董事,2022年10月至今担任浙江维康药业股份有限公司独立董事,2023年11月至今任公司董事。
English Translation 英文译文 · Organisation Names in Chinese 机构名称保留中文Mr. Wu Bin, born in June 1960, holds Chinese nationality, has no permanent foreign residency, holds a master's degree, is a registered senior consultant, senior economist, and practicing pharmacist. He has successively served as Deputy Section Chief of the Enterprise Management Section of 山西省医药公司, Deputy Division Chief of the Commercial Division of 山西省医药管理局, Deputy Manager of 山西省药材公司, Director of the Economic Operations Department and Assistant to the General Manager of 山西省医药集团有限公司, and Executive Vice President of 中国医药商业协会. He has been a member of the Expert Committee of 中国医药企业管理协会 since August 2020. Director of 老百姓大药房连锁股份有限公司 (Lbx Pharmacy Chain) from May 2016 to present, Independent Director of 瑞康医药集团股份有限公司 (Realcan Pharmaceutical Group) from September 2016 to May 2023, Independent Director of 广誉远中药股份有限公司 (Guangyuyuan) from March 2017 to January 2023, Independent Director of 哈药集团人民同泰医药股份有限公司 (HPGC Renmintongtai Pharmaceutical) from July 2019 to present, Independent Director of 德展大健康股份有限公司 (Dezhan Healthcare) from August 2021 to present, Independent Director of 浙江维康药业股份有限公司 (Zhejiang Wecome Pharmaceutical) from October 2022 to present, Director of the Company from November 2023 to present.